FY2027 EPS Estimates for Inozyme Pharma Increased by Analyst

Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - Investment analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for shares of Inozyme Pharma in a note issued to investors on Tuesday, March 11th. HC Wainwright analyst E. White now expects that the company will earn ($0.73) per share for the year, up from their prior estimate of ($1.57). HC Wainwright currently has a "Buy" rating and a $16.00 target price on the stock. The consensus estimate for Inozyme Pharma's current full-year earnings is ($1.59) per share.

A number of other research analysts have also commented on the company. Wedbush reissued an "outperform" rating and set a $7.00 price objective (down previously from $12.00) on shares of Inozyme Pharma in a report on Monday, March 10th. Piper Sandler lowered their target price on Inozyme Pharma from $30.00 to $23.00 and set an "overweight" rating on the stock in a report on Tuesday, March 11th. Wells Fargo & Company lowered their target price on Inozyme Pharma from $14.00 to $11.00 and set an "overweight" rating on the stock in a report on Monday, January 13th. Needham & Company LLC lowered their target price on Inozyme Pharma from $23.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. Finally, Raymond James lowered their target price on Inozyme Pharma from $24.00 to $12.00 and set an "outperform" rating on the stock in a report on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Inozyme Pharma currently has a consensus rating of "Buy" and a consensus price target of $14.56.

Remove Ads

Inozyme Pharma Stock Down 4.5 %

Shares of NASDAQ INZY traded down $0.05 during mid-day trading on Friday, reaching $0.97. 461,501 shares of the company traded hands, compared to its average volume of 507,275. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. The stock has a market cap of $62.54 million, a PE ratio of -0.62 and a beta of 1.32. The company's fifty day moving average is $1.40 and its two-hundred day moving average is $3.17. Inozyme Pharma has a fifty-two week low of $0.94 and a fifty-two week high of $7.80.

Hedge Funds Weigh In On Inozyme Pharma

Several hedge funds and other institutional investors have recently modified their holdings of INZY. OneDigital Investment Advisors LLC lifted its position in shares of Inozyme Pharma by 51.5% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 20,000 shares of the company's stock worth $105,000 after buying an additional 6,800 shares during the period. Eventide Asset Management LLC lifted its position in shares of Inozyme Pharma by 5.0% during the 3rd quarter. Eventide Asset Management LLC now owns 4,134,436 shares of the company's stock worth $21,623,000 after buying an additional 198,216 shares during the period. Readystate Asset Management LP bought a new position in shares of Inozyme Pharma during the 3rd quarter worth approximately $100,000. State Street Corp lifted its position in shares of Inozyme Pharma by 5.0% during the 3rd quarter. State Street Corp now owns 1,050,420 shares of the company's stock worth $5,494,000 after buying an additional 50,386 shares during the period. Finally, Wellington Management Group LLP lifted its position in shares of Inozyme Pharma by 11.9% during the 3rd quarter. Wellington Management Group LLP now owns 260,719 shares of the company's stock worth $1,364,000 after buying an additional 27,739 shares during the period. Institutional investors own 88.30% of the company's stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.